BR112021019128A2 - Anticorpos de depleção de membro 1 da subfamília g do receptor tipo lectina de célula assassina (klrg1) - Google Patents
Anticorpos de depleção de membro 1 da subfamília g do receptor tipo lectina de célula assassina (klrg1)Info
- Publication number
- BR112021019128A2 BR112021019128A2 BR112021019128A BR112021019128A BR112021019128A2 BR 112021019128 A2 BR112021019128 A2 BR 112021019128A2 BR 112021019128 A BR112021019128 A BR 112021019128A BR 112021019128 A BR112021019128 A BR 112021019128A BR 112021019128 A2 BR112021019128 A2 BR 112021019128A2
- Authority
- BR
- Brazil
- Prior art keywords
- cadherin
- klrg1
- antibodies
- receptor
- killer cell
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962831713P | 2019-04-09 | 2019-04-09 | |
| PCT/US2020/027498 WO2020210512A1 (en) | 2019-04-09 | 2020-04-09 | Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021019128A2 true BR112021019128A2 (pt) | 2022-01-04 |
Family
ID=72748720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021019128A BR112021019128A2 (pt) | 2019-04-09 | 2020-04-09 | Anticorpos de depleção de membro 1 da subfamília g do receptor tipo lectina de célula assassina (klrg1) |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11180561B2 (https=) |
| EP (1) | EP3952999A4 (https=) |
| JP (1) | JP7560476B2 (https=) |
| KR (1) | KR20210150506A (https=) |
| CN (1) | CN114040800B (https=) |
| AU (1) | AU2020272939A1 (https=) |
| BR (1) | BR112021019128A2 (https=) |
| CA (1) | CA3136625A1 (https=) |
| IL (1) | IL287044A (https=) |
| MX (1) | MX2021012171A (https=) |
| SG (1) | SG11202110610VA (https=) |
| WO (1) | WO2020210512A1 (https=) |
| ZA (1) | ZA202107414B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020060781A1 (en) | 2018-09-17 | 2020-03-26 | Abcuro, Inc. | Anti-klrg1 antibodies |
| WO2022056289A1 (en) * | 2020-09-11 | 2022-03-17 | National Jewish Health | Methods and compositions for treating respiratory diseases or conditions related to innate lymphoid cells |
| AU2022246164A1 (en) * | 2021-03-26 | 2023-09-28 | The Brigham And Women’S Hospital, Inc. | Anti-klrg1 antibodies |
| WO2022204529A1 (en) * | 2021-03-26 | 2022-09-29 | Abcuro, Inc. | Anti-klrg1 antibodies |
| MX2024001277A (es) * | 2021-07-26 | 2024-02-15 | Abcuro Inc | Anticuerpos agotadores del miembro 1 de la subfamilia g del receptor tipo lectina de celulas asesinas (klrg1). |
| WO2024072872A2 (en) * | 2022-09-27 | 2024-04-04 | The Brigham And Women's Hospital, Inc. | Klrg1 signalling therapy for infectious disease |
| WO2025147544A1 (en) | 2024-01-02 | 2025-07-10 | Abcuro, Inc. | Methods of treating inclusion body myositis (ibm) |
| WO2026072990A1 (en) | 2024-09-27 | 2026-04-02 | Abcuro, Inc. | Methods of treating t-cell large granular lymphocytic leukemia |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| WO2001070805A2 (en) | 2000-03-17 | 2001-09-27 | Gemini Science, Inc. | Soluble mast cell function associated antigen (mafa) pharmaceutical compositions and methods of making and using them |
| GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
| JP3536039B2 (ja) | 2001-05-08 | 2004-06-07 | 独立行政法人 科学技術振興機構 | Ｈｔｌｖ−ｉ腫瘍に対する抗腫瘍抗原又はその抗原エピトープ |
| GB0114107D0 (en) | 2001-06-09 | 2001-08-01 | Medical Res Council | Respiratory syncytial virus |
| CA2680344A1 (en) | 2007-03-14 | 2008-11-20 | Woodruff Emlen | Humaneered anti-factor b antibody |
| BR112012000536A2 (pt) | 2009-07-08 | 2020-08-11 | Kymab Limited | métodos para produção de anticorpo ou cadeia leve ou pesada de anticorpo específico para um antígeno desejado, para produção de anticorpo ou cadeia de anticorpo e seu uso, composição farmacêutica e derivado de anticorpo quimérico |
| JP2012025694A (ja) | 2010-07-23 | 2012-02-09 | Asahi Kasei Kuraray Medical Co Ltd | 癌治療剤 |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| KR20140138971A (ko) | 2012-03-28 | 2014-12-04 | 제넨테크, 인크. | 항-hcmv 이디오타입 항체 및 이들의 용도 |
| WO2016013672A1 (ja) | 2014-07-25 | 2016-01-28 | 国立研究開発法人理化学研究所 | メモリーインバリアントｎｋｔ細胞マーカー |
| CA3005491A1 (en) | 2015-11-17 | 2017-05-26 | Glaxosmithkline Intellectual Property Development Limited | Binding agonists for treatment of neurological and other disorders |
| UA126115C2 (uk) * | 2016-03-08 | 2022-08-17 | Янссен Байотек, Інк. | Антитіло до gitr |
| WO2017210523A1 (en) * | 2016-06-03 | 2017-12-07 | The Brigham And Women's Hospital | Klrg1 signaling therapy |
| AU2017326003A1 (en) | 2016-09-16 | 2019-04-11 | Children's Medical Center Corporation | KLRG1 depletion therapy |
| US20210002373A1 (en) * | 2018-03-01 | 2021-01-07 | Nextcure, Inc. | KLRG1 Binding Compositions and Methods of Use Thereof |
-
2020
- 2020-04-09 EP EP20788331.5A patent/EP3952999A4/en active Pending
- 2020-04-09 US US16/844,747 patent/US11180561B2/en active Active
- 2020-04-09 BR BR112021019128A patent/BR112021019128A2/pt unknown
- 2020-04-09 SG SG11202110610VA patent/SG11202110610VA/en unknown
- 2020-04-09 AU AU2020272939A patent/AU2020272939A1/en active Pending
- 2020-04-09 CN CN202080036935.9A patent/CN114040800B/zh active Active
- 2020-04-09 JP JP2021559904A patent/JP7560476B2/ja active Active
- 2020-04-09 MX MX2021012171A patent/MX2021012171A/es unknown
- 2020-04-09 CA CA3136625A patent/CA3136625A1/en active Pending
- 2020-04-09 KR KR1020217036417A patent/KR20210150506A/ko active Pending
- 2020-04-09 WO PCT/US2020/027498 patent/WO2020210512A1/en not_active Ceased
-
2021
- 2021-10-01 ZA ZA2021/07414A patent/ZA202107414B/en unknown
- 2021-10-06 IL IL287044A patent/IL287044A/en unknown
- 2021-10-20 US US17/506,313 patent/US12139541B2/en active Active
-
2024
- 2024-09-12 US US18/883,109 patent/US20250101114A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020210512A1 (en) | 2020-10-15 |
| US20220089747A1 (en) | 2022-03-24 |
| EP3952999A4 (en) | 2023-01-25 |
| US20250101114A1 (en) | 2025-03-27 |
| CN114040800A (zh) | 2022-02-11 |
| JP7560476B2 (ja) | 2024-10-02 |
| JP2022528721A (ja) | 2022-06-15 |
| MX2021012171A (es) | 2021-12-10 |
| KR20210150506A (ko) | 2021-12-10 |
| WO2020210512A9 (en) | 2020-11-19 |
| AU2020272939A1 (en) | 2021-11-11 |
| IL287044A (en) | 2021-12-01 |
| AU2020272939A8 (en) | 2021-12-02 |
| EP3952999A1 (en) | 2022-02-16 |
| US11180561B2 (en) | 2021-11-23 |
| US20200325233A1 (en) | 2020-10-15 |
| CN114040800B (zh) | 2024-09-20 |
| CA3136625A1 (en) | 2020-10-15 |
| SG11202110610VA (en) | 2021-10-28 |
| ZA202107414B (en) | 2023-02-22 |
| US12139541B2 (en) | 2024-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021019128A2 (pt) | Anticorpos de depleção de membro 1 da subfamília g do receptor tipo lectina de célula assassina (klrg1) | |
| CL2023002239A1 (es) | Anticuerpos de b7-h4 y métodos para usarlos | |
| AR133653A2 (es) | Constructos de anticuerpo biespecíficos que se ligan a células t | |
| PE20211396A1 (es) | Receptores quimericos de dll3 y metodos para su uso | |
| WO2020016662A3 (en) | Antibodies specific to trophoblast antigen 2 (trop2) | |
| MX2025007735A (es) | Anticuerpos anti-il36r | |
| CL2024003661A1 (es) | Anticuerpo anti-trem2 humano; método de producción; y su uso. | |
| CR20190440A (es) | Receptores de unión a antígeno mejorados | |
| PH12020552138A1 (en) | Bcma chimeric antigen receptors and uses thereof | |
| PE20180330A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 y metodos para su uso | |
| WO2016164731A3 (en) | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell | |
| PE20231958A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
| BR112021017756A2 (pt) | Piperidinila bicíclica fundida e compostos relacionados como moduladores do receptor c5a | |
| EA201691925A1 (ru) | Биспецифические антитела, которые связываются с cd38 и cd3 | |
| EA201890443A1 (ru) | Биспецифичные моновалентные диатела, способные связывать b7-h3 и cd3, и их применение | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| PE20211418A1 (es) | Receptores quimericos y metodos de uso de los mismos | |
| MX2020009463A (es) | Receptor de antígeno quimérico de receptor de il-13 alfa 2 (il13ra2) para inmunoterapia de células t específica para tumor. | |
| PE20230839A1 (es) | Agentes de union a lair-1 y metodos para su uso | |
| MX374929B (es) | RECEPTOR QUIMERICO DE ANTIGENO anti-EGFRvlll HUMANIZADO Y USOS DEL MISMO. | |
| RU2017117596A (ru) | Связывающие молекулы, специфичные в отношении CD73, и пути их применения | |
| MX2015013194A (es) | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 humanizado. | |
| MX2016012830A (es) | Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos. | |
| MX382284B (es) | Anticuerpo que se une a fcrn para usarse en el tratamiento de enfermedades autoinmunes. | |
| PE20060376A1 (es) | ANTICUERPO MONOCLONAL HUMANIZADO O QUIMERICO COMO INHIBIDOR DE hIL-3 |